Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Watson Says Received Favorable Ruling Over Generic Sanctura XR

04/03/2012 | 06:19pm US/Eastern

Watson Pharmaceuticals Inc. (>> Watson Pharmaceuticals, Inc.) said it received a favorable court ruling over a patent dispute with Allergan Inc. (AGN) and its business partners regarding Watson's plans for a generic version of an overactive bladder medication.

Allergan and its partners in 2009 sued Watson and its business partners, alleging infringement of patents related to Allergan's Sanctura XR drug.

Watson said Tuesday a U.S. District Court in Delaware found several Sanctura XR patents invalid, benefiting Watson and allowing it to potentially move forward with its abbreviated new drug application for generic version of the drug, which is pending with the Food and Drug Administration.

An Allergan representative wasn't immediately available for comment.

Watson has seen strong sales of its generics as health-care companies and consumers try to reduce spending on health-related products and services. Watson is trying to expand its brand-name drug business, though it recently hit a regulatory setback with a proposed new drug to prevent premature births.

The company benefited from its introduction of authorized generic versions of Johnson & Johnson's (JNJ) Concerta treatment for attention-deficit/hyperactivity disorder in May, as well as Pfizer's (PFE) Lipitor cholesterol-lowering drug in November.

Watson in February said its fourth-quarter profit surged as the introduction of generic Lipitor and other products boosted sales.

Watson's shares closed Tuesday at $66.96 and were down 6 cents after hours. Allergan's shares closed at $95.27 and were off 10 cents after hours.

-By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108; ben.rubin@dowjones.com

Stocks mentioned in the article : Watson Pharmaceuticals, Inc.
React to this article
Latest news on ACTAVIS INC
06:15a Hikma to buy Boehringer's U.S. generic drug business for $2.65 billion
03:25a Hikma to buy Boehringer's U.S. generics unit for $2.65 billion
07/27 Mylan independence from Teva's embrace comes with a price
07/27 Mylan independence from Teva's embrace comes with a price
07/27DJMylan's Leverage to Resist Teva Deal Reveals Shift in Rules
07/27 Allergan CEO, fresh off one deal, sets sights on others
07/27 Wall Street drops as China stock slump stokes growth fears
07/27DJMARKET SNAPSHOT : U.S. Stocks Follow China's Rout With 5th Straight Decline
07/27DJU.S. Stocks Follow Global Markets Lower
07/27DJMARKET SNAPSHOT : U.S. Stocks Follow China's Rout With
Advertisement
Income Statement Evolution
More Financials